

Intercell AG
Document according to section 75a of the Austrian Stock Exchange Act (SEA)
of mandatory announcements during the fiscal year 2007

Date	Type	Description	Source
15.1.2007	Ad-hoc announcement	Acquisition of 100 % of Pelias shares in an all-share deal for 349,815 new Intercell shares; product portfolio strengthened by clinical stage Pseudomonas vaccine candidate	www.intercell.com
5.3.2007	Ad-hoc announcement Q4 & full year results	Announcement of Q4 and preliminary full year 2006 results	www.intercell.com
14.3.2007	Ad-hoc announcement	Novel tuberculosis vaccine shows promising immunogenicity and safety profile	www.intercell.com
21.03.2007	Announcement according to section 93 SEA	Changes in shares of voting rights: Apax Europe IV-A L.P. sold its entire share of the voting rights of more than 10 %	Wiener Zeitung
4.4.2007	Ad-hoc announcement	Regulatory approval to start pediatric clinical trials for Japanese Encephalitis (JE) Vaccine in India obtained	www.intercell.com
27.4.2007	Ad-hoc announcement	Publication of 2006 Annual Report	www.intercell.com
14.5.2007	Ad-hoc announcement Q1 results	Announcement of Q1 results and update on development programs	www.intercell.com
18.5.2007	Ad-hoc announcement	Staphylococcus aureus vaccine development on track - safe and immunogenic in Phase I clinical trials	www.intercell.com
19.5.2007	AGM invitation	Invitation for the Annual General Meeting held on June 15, 2007	Wiener Zeitung
19.5.2007	Report according to sec. 98 (3) and 159 (2) lit 3 Stock Corporations Act	Report of the Management Board on the grant of stock options to the members of the Supervisory Board	Wiener Zeitung

Date	Type	Description	Source
18.6.2007	Ad-hoc announcement	Development of the next generation Flu vaccines commenced – Phase I for Influenza vaccine adjuvanted with Intercell’s IC31™ started	www.intercell.com
2.7.2007	Ad-hoc announcement	Announcement of the formation of a strategic partnership between Intercell and Novartis to drive vaccines innovation	www.intercell.com
10.07.2007	Publication according to section 4 and 5 Publication Ordinance (<i>VöffVO</i>)	Announcement of the intended sale of treasury shares in connection with the exercise of employee stock options	euroadhoc European distribution service
12.7.2007	Disclosure according to section 93 subs. 2 SEA	ATI Vermögenstreuhandgesellschaft m.b.H reduced its share in the voting rights from more than 5 % to 4.9 %.	www.issuerinfo.oekb.at
16.7.2007	Ad-hoc announcement	First child vaccinated with Intercell Japanese Encephalitis (JE) Vaccine in India - pediatric Phase II clinical trial started	www.intercell.com
19.07.2007	Publication according to section 7 Publication Ordinance (<i>VöffVO</i>)	Announcement of the completion of the sale of treasury shares in connection with the exercise of employee stock options	www.intercell.com
24.7.2007	Announcement according to section 93 SEA	Announcement of new total number of voting rights of 40.721.707 effective as of 13.07.2007	www.issuerinfo.oekb.at
13.8.2007	Ad-hoc announcement Q2/H2 results	Announcement of Q2 and Half Year financial report and business update	www.intercell.com
20.8.2007	Ad-hoc announcement	Intercell’s therapeutic Hepatitis C vaccine meets primary endpoints in Phase II interim analysis	www.intercell.com
30.8.2007	Ad-hoc announcement	Intercell management board resolves €150 million capital increase – HSR waiting period for the strategic partnership with Novartis has expired	www.intercell.com

Date	Type	Description	Source
31.8.2007	Report according to section 171 and 53 Stock Corporation Act	Report on issuance of 4.8 million new shares of common stock at an issue price of €31.25 per share to Novartis Pharma AG and exclusion of subscription rights of existing shareholders	www.intercell.com
19.7.2007	Listing prospectus according to section 74 SEA	Prospectus dated September 19, 2007 for admission to listing of 4,800,000 new shares of common stock	www.intercell.com
28.9.2007	Disclosure according to section 93 SEA	Announcement of new total number of voting rights of 45.521.707 and of an increase of the share in the voting rights of Novartis AG to 15.9 percent	www.issuerinfo.oekb.at
19.11.2007	Ad-hoc announcement Q3 results	Announcement of Q3 results and business update	www.intercell.com
23.11.2007	Ad-hoc announcement	Receipt of next EUR 80 million payment from Novartis alliance	www.intercell.com
4.12.2007	Ad-hoc announcement	Announcement of the initiation of a clinical trial for a novel vaccine candidate against tuberculosis	www.intercell.com
6.12.2007	Ad-hoc announcement	Submission of marketing authorization application (MAA) to EMEA for licensure of Japanese Encephalitis Vaccine	www.intercell.com
14.12.2007	Report according to section 159(3) and (2) Z 3 Stock Corporation Act	Report of the management board on the issuance of stock options to members of the management board and employees	euroadhoc European distribution service
16.12.2007	Ad-hoc announcement	Receipt of milestone payment from Merck & Co. Inc triggered by initiation of Phase II clinical trial of investigational vaccine to prevent S. aureus infection	www.intercell.com
20.12.2007	Ad-hoc announcement	Submission of US Biological License Application (BLA) to FDA for licensure of Japanese Encephalitis vaccine	www.intercell.com